11 Jun 2015 13:00
VERONA PHARMA PLC - Result of AGMVERONA PHARMA PLC - Result of AGM
PR Newswire
London, June 11
Verona Pharma plc
("Verona Pharma" or the "Company")
Result of AGM
11 June 2015, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that all resolutions proposed at the Annual General Meeting (AGM) held today were duly passed.
A presentation on Verona Pharma made by its Chief Executive Officer, Dr. Jan-Anders Karlsson, will be available to view on the Company’s website http://www.veronapharma.com/.
-Ends-
For further information please contact:
| Verona Pharma plc | Tel: +44 (0) 20 7863 3300 |
| Jan-Anders Karlsson, CEO | |
| N+1 Singer | Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | |
| FTI Consulting | Tel: +44 (0)20 3727 1000 |
| Julia Phillips / Simon Conway |
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has recently received a Venture and Innovation Award from the UK Cystic Fibrosis Trust.